European Respiratory Society Congress
28-30 September 2025
Join us at Booth #H.12 to discover how Zephyr® Valves can help support your clinical decisions when medications aren’t enough.
COPD stole their breath. You can give it back.
This year at ERS 2025, we’re celebrating you — the physicians who fight for every breath and guide patients through the most advanced stages of severe COPD/emphysema.
Find Us
What to Expect at Booth H.12
Visit us to explore how Zephyr Valves —our evidence-based treatment for severe COPD/emphysema — can support your clinical decisions when medications aren’t enough.
-
Hands-On Demonstration
Practice placing Zephyr Valves in a demo lung and experience our bronchoscopic solution firsthand.
-
Explore the Clinical Evidence
Learn how Zephyr Valves may help patients breathe easier, improve exercise capacity, and enjoy a better quality of life¹ — even when medications aren’t enough.
-
Talk to Our Team
Get expert insight on patient selection and assessment tools, discuss patient cases, and explore how the therapy could fit into your practice.
Your heroes are ready — are you?
Step into your superhero moment that celebrates the power behind your practice. Take part in our photo contest for a chance to win a prize:
- Visit Booth H.12 and take a pic at our photo wall.
- Post your photo on LinkedIn, Instagram, or X using the hashtag #ZephyrPower and tag Pulmonx.
- Winners will be announced on the final day of ERS 2025.
*Contest open to ERS 2025 attendees only.
Helping Patients Breathe Easier, Do More & Enjoy Life¹
Zephyr Valves are a proven treatment for breathlessness from severe COPD/emphysema
Discover the Science Behind Zephyr Valves
The Zephyr Valve is a clinically-proven bronchoscopic treatment for patients with severe COPD/emphysema.
¹Criner, G et al. Am J Resp Crit Care Med. 2018 Nov 1;198(9):1151–1164
²Hartman JE, Welling JBA et. al. Respir Med. 2022; doi:10.1016/j.rmed.2022.106825; Single-center retrospective study of 1471 COPD patients referred for BLVR.
483 patients undergoing bronchoscopic lung volume reduction compared to patients who were not eligible for BLVR (n=988).
Sessions of Interest
The Zephyr Valve is a standard of care treatment option. Check out the presentations during ERS 2025, highlighting endobronchial valves (EBV) as a treatment option for severe COPD/emphysema.
Poster Session PS-1
Comprehensive approaches to COPD: risk, treatment and outcomes
A. Raza
Philadelphia, United States
E. Alharbi
Leicester, United Kingdom
Sept 28, 2025 – 08:00 – 09:30
Poster Session PS-11
Environmental sustainability in the management of airway diseases: novel alpha- 1 antitrypsin data and innovations in drug delivery
S. Tielke
Oberhausen-Rheinhausen, Germany
Sept 28, 2025 – 08:00 – 09:30
Poster session PS-24
Challenges in thoracic surgery
M. Charles-Rudwick
Norwich, United Kingdom
H. Stubbs
Glasgow, United Kingdom
Sept 28, 2025 – 08:00 – 09:30
Poster Session PS-39
Emphysema and chronic bronchitis interventional pulmonology treatment
J. Welling
Groningen, The Netherlands
T. Egenod
Limoges, France
A. Raza
Philadelphia, United States
T. Sgarbossa
Berlin, Germany
T. Sgarbossa
Berlin, Germany
R. Eberhardt
Hamburg, Germany
J. Brock
Heidelberg, Germany
W. Janssens
Leuven, Belgium
G. Wang
Beijing, China
M. Mineshita
Kawasaki, Kanagawa, Japan
J. Cordero Marquez
Torrejon de Ardoz, Spain
E. ter Haar
Groningen, The Netherlands
Sept 28, 2025 – 08:00 – 09:30
Poster Session PS-4
Improving outcome measurement in chronic lung disease
K. Boza
Hove, United Kingdom
Sept 28, 2025 – 12:30 – 14:00
Poster Session PS-3
Emerging digital interventions in respiratory care: the evidence and transformative impacts
B. Cavazzutti
Bergamo, Italy
Sept 29, 2025 – 08:00 – 09:30
Poster Session PS-10
Revisiting established asthma and COPD therapies: new data and evolving perspectives
N. Bautin
Lille cedex, France
N. Eikelis
Melbourne, Australia
Sept 29, 2025 – 08:00 – 09:30
Symposium Session 368 (5B)
Pleural disease: the global view
S. Walker
Bristol (Avon), United Kingdom
Sept 29, 2025 – 15:30 – 17:00
Poster session PS-1
When the heart meets the lungs: cardiovascular impacts of pulmonary and post-COVID conditions
J. Saccomanno
Berlin, Germany
Sept 30, 2025 – 08:00 – 09:30
Auditorium
LIVE Endoscopy Session 2: COPD, lung nodules and pleural disease
Professor Dirk Jan Slebos, MD PhD
Groningen, The Netherlands
Stephanie Everaerts, MD PhD
Leuven, Belgium
Sept 30, 2025 – 11:15 – 11:45
Poster Session PS-18
Asthma and COPD: from mechanisms to clinical issues
R. Singh
London, United Kingdom
Sept 30, 2025 – 12:30 – 14:00
Poster Session PS-39
Innovations in thoracic imaging: functional, structural and interventional insights
K. Patel
London, United Kingdom
Sept 30, 2025 – 12:30 – 14:00
Watch testimonials from healthcare professionals on EBV as a part of standard of care treatment option and learn about evidence recommending Zephyr Valves as a treatment for severe COPD/emphysema patients.
GLO-EN-2742-v1